Patents Assigned to Cedars-Sinai Medical Center
  • Patent number: 11992699
    Abstract: A UV light delivery device for performing intra-corporeal ultraviolet therapy is provided. The device includes an elongated body separated by a proximal end and a distal end. The device also includes a UV light source configured to be received at the receiving space. In some examples, the UV light source is configured to emit light with wavelengths with significant intensity between 320 nm and 410 nm and is utilized in conjunction with an endotracheal tube or a nasopharyngeal airway.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: May 28, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Ali Rezaie, Mark Pimentel, Gil Y. Melmed, Ruchi Mathur, Gabriela Guimaraes Sousa Leite
  • Patent number: 11994523
    Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: May 28, 2024
    Assignees: ABBOTT LABORATORIES, CEDARS-SINAI MEDICAL CENTER
    Inventors: Jennifer Van Eyk, Beth McQuiston, Saul Datwyler, Raj Chandran, Vidya Venkatraman, Shenyan Zhang
  • Patent number: 11987780
    Abstract: Described herein is functionalized glass allowing for robust attachment of extracellular matrix proteins (ECM) withstanding extended culturing periods. By first treating glass with a sulfur silane reagent, the treated glass can be activated via an amine-sulfur linker, after which ECM proteins are attached to the linker. The Inventors observed that this glass treatment combination (sulfur silane-linker-ECM) resisted degradation when compared to conventional surface coatings, such as poly-L-orthinine coated glass.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: May 21, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Alexander Laperle, Clive Svendsen
  • Publication number: 20240158757
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors, including generation of iPSCs from lymphoblastoid B-cells and lymphoblastoid B-cell lines. Such methods and compositions find use in regenerative medicine applications.
    Type: Application
    Filed: July 14, 2023
    Publication date: May 16, 2024
    Applicant: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren Ornelas, Robert Barrett
  • Publication number: 20240159772
    Abstract: Described herein are methods and systems for detecting and/or distinguishing irritable bowel syndrome (IBS) from inflammatory bowel disease (IBD) and celiac disease. The methods and systems can utilize the detection of anti-CdtB antibodies and/or anti-vinculin antibodies to detect IBS, distinguish IBS from IBD and/or celiac disease. Further described are methods for selecting a therapy to treat IBS, IBD or celiac disease.
    Type: Application
    Filed: May 19, 2023
    Publication date: May 16, 2024
    Applicant: Cedars-Sinai Medical Center
    Inventors: Mark Pimentel, Christopher Chang
  • Patent number: 11981918
    Abstract: Induced Pluripotent Stem Cell (Ipsc) technology enables the generation and study of living brain tissue relevant to Parkinson's disease (PD) ex vivo. Utilizing cell lines from PD patients presents a powerful discovery system that links cellular phenotypes observed in vitro with real clinical data. Differentiating patient-derived iPSCs towards a dopaminergic (DA) neural fate revealed that these cells exhibit molecular and functional properties of DA neurons in vitro that are observed to significantly degenerate in the substantia nigra of PD patients. Clinical symptoms that drive the generation of other relevant cell types may also yield novel PD-specific phenotypes in vitro that have the potential to lead to new therapeutic avenues for patients with PD.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: May 14, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Alexander Laperle, Samuel Sances, Nur Yucer, Clive N. Svendsen
  • Patent number: 11970714
    Abstract: Described herein are methods and compositions related to generation of induced pluripotent stem cells (iPSCs). Improved techniques for establishing highly efficient, reproducible reprogramming using non-integrating episomal plasmid vectors. Using the described reprogramming protocol, one is able to consistently reprogram non-T cells with close to 100% success from non-T cell or non-B cell sources. Further advantages include use of a defined reprogramming media E7 and using defined clinically compatible substrate recombinant human L-521. Generation of iPSCs from these blood cell sources allows for recapitulation of the entire genomic repertoire, preservation of genomic fidelity and enhanced genomic stability.
    Type: Grant
    Filed: July 2, 2020
    Date of Patent: April 30, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dhruv Sareen, Loren A. Ornelas, Clive Svendsen
  • Publication number: 20240124573
    Abstract: Novel therapeutic protocols are provided relating to the use of an anti-IL-6 antibody, e.g., Clazakizumab, in order to prevent, stabilize, reduce or arrest antibody mediated rejection responses in patients receiving solid organ transplants, e.g., patients receiving transplanted kidney, heart, liver, lungs, pancreas, intestines or combinations of any of the foregoing. Also novel therapeutic protocols are provided pertaining to the use of an anti-IL-6 antibody, e.g., Clazakizumab, as part of a desensitization protocol for treating highly sensitized subjects waiting for and/or after allograft transplants, e.g., patients who are to receive solid organ transplants, e.g., kidney, heart, liver, lungs, pancreas, intestines, skin or combinations of any of the foregoing. The foregoing treatments may be effected in combination with one or more other immunosuppressant regimens or other desensitization procedures.
    Type: Application
    Filed: August 10, 2023
    Publication date: April 18, 2024
    Applicants: VITAERIS, INC., CEDARS-SINAI MEDICAL CENTER
    Inventors: Kevin CHOW, Edward CHONG, Nuala MOONEY, Julien LION, Stanley C. JORDAN
  • Publication number: 20240115569
    Abstract: The invention of the present disclosure relates to methods for diagnosing and for treating a progressive lung disease in a subject. In various embodiments, the method for treating a progressive lung disease in a subject includes administering a pharmaceutical composition comprising a Human Epidermal Growth Factor Receptor 2 (HER2) blocking agent and a pharmaceutically acceptable carrier to the subject, wherein the method improves clinical outcome compared to an untreated control.
    Type: Application
    Filed: February 11, 2022
    Publication date: April 11, 2024
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Paul W. Noble, Dianhua Jiang
  • Publication number: 20240115699
    Abstract: We combined single nuclei RNA sequencing with spatial transcriptomics and single-cell resolution spatial proteomic analysis of human bladder cancer to identify an epithelial subpopulation with therapeutic response prediction ability. These cells express Cadherin 12 (CDH12, N-Cadherin 2), catenins, and other epithelial markers. CDH12-enriched tumors define patients with poor outcome following surgery with or without neoadjuvant chemotherapy (NAC), whereas CDH12-enriched tumors have a superior response to immune checkpoint therapy (ICT). Patient stratification by tumor CDH12 enrichment offered better prediction outcome than established bladder cancer subtypes. The CDH12 population resembles an undifferentiated state with chemoresistance. CDH12-enriched cells express PD-L1 and PD-L2 and co-localize with exhausted T-cells, possibly mediated through CD49a (ITGA1), likely explaining ICT efficacy in these tumors.
    Type: Application
    Filed: June 6, 2022
    Publication date: April 11, 2024
    Applicant: Cedars-Sinai Medical Center
    Inventors: Dan Theodorescu, Simon Knott, Kenneth Gouin, Nathan Ing, Charles Rosser
  • Publication number: 20240093154
    Abstract: Diabetes is a clinical condition that affects millions of people worldwide, and is treated by insulin replacement therapies. New strategies to create scalable and compatible pancreatic islets containing insulin-producing beta cells are necessary as an alternative to limited supply of cadaveric islets or multiple exogenous insulin applications. Improvements are still necessary since many immature polyhormonal cells remain, and cannot attain a monohormonal state. During human development, pancreas co-develops with endothelium and shares signals, allowing for better maturation of beta cells, and this is not included in the current differentiation protocols. The organchip microfluidic devices allows dynamic co-culture of different cells, thus resembling in vivo physiology. Here the Inventors establish organ-chip models co-culturing human iPSC-derived pancreatic precursors with iPSC-derived endothelial cells to obtain more functional and monohormonal iPSC-derived beta cells.
    Type: Application
    Filed: January 31, 2022
    Publication date: March 21, 2024
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Roberta de Souza Santos
  • Publication number: 20240095912
    Abstract: Systems and methods are disclosed for applying attenuation correction to single photon emission computed tomography (SPECT) imaging data for myocardial perfusion imaging (MPI) studies. SPECT-MPI imaging data can be provided to a deep-learning model to automatically generate simulated computed tomography attenuation correction (CT-AC) images from the non-corrected (NC) SPECT-MPI imaging data. These simulated CT-AC images can then be used to perform attenuation correction on the SPECT-MPI imaging data to generate corrected SPECT-MPI imaging data. The deep-learning model can be trained using corresponding pairs of non-corrected SPECT-MPI imaging data and traditional CT-AC imaging data. The deep-learning model can be a conditional generative adversarial neural network (cGAN).
    Type: Application
    Filed: September 12, 2023
    Publication date: March 21, 2024
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Piotr SLOMKA, Aakash Shanbhag
  • Patent number: 11935158
    Abstract: A method for performing real-time magnetic resonance (MR) imaging on a subject is disclosed. A prep pulse sequence is applied to the subject to obtain a high-quality special subspace, and a direct linear mapping from k-space training data to subspace coordinates. A live pulse sequence is then applied to the subject. During the live pulse sequence, real-time images are constructed using a fast matrix multiplication procedure on a single instance of the k-space training readout (e.g., a single k-space line or trajectory), which can be acquired at a high temporal rate.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: March 19, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Anthony Christodoulou, Zhaoyang Fan, Debiao Li, Pei Han
  • Publication number: 20240084262
    Abstract: The present invention provides for methods of differentiating induced pluripotent stem cells into pancreatic progenitor cells, pancreatic ductal cells, pancreatic endocrine cells, pancreatic acinar cells, and pancreatic organoids. Cells created by these methods are also provided. Further provided are disease models and methods of drug screening.
    Type: Application
    Filed: October 29, 2021
    Publication date: March 14, 2024
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Dhruv Sareen, Stephen Pandol, Syairah Hanan Shaharuddin, Victoria Wang, Michael Edison P. Ramos, Aurelia Lugea, Richard T. Waldron
  • Publication number: 20240087126
    Abstract: Systems and methods are disclosed for automatically performing motion correction in dynamic positron emission tomography scans, such as dynamic positron emission tomography myocardial perfusion imaging studies. An automated algorithm can be used. The algorithm can use simplex iterative optimization of a count-based cost-function customized to different dynamic phases for performing frame-by-frame motion correction.
    Type: Application
    Filed: September 12, 2023
    Publication date: March 14, 2024
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Chih-Chun Wei, Piotr Slomka, Serge D. Van Kriekinge
  • Publication number: 20240076629
    Abstract: Described herein is the production neural progenitor cell lines (NPCs) derived from human induced pluripotent stem cells (iPSCs). These iPSC-derived NPCs engraft efficiently into the spinal cord of ALS animal models and provide neuroprotection to diseased motor neurons, similar to the fetal-derived cells used in clinical study. Clonal lines were generated with a single copy GDNF construct inserted in the AAVS1 safe landing site, including inducible expression of GDNF expression. These new iPSC-derived NPC lines are scalable to clinically relevant production volumes, uniformly produce GDNF, are safe, and represent a promising new combination therapy for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS).
    Type: Application
    Filed: October 22, 2020
    Publication date: March 7, 2024
    Applicant: Cedars-Sinai Medical Center
    Inventors: Alexander LAPERLE, Aaron FULTON, Clive N. SVENDSEN
  • Patent number: 11920160
    Abstract: Production of beta-cells from stem cells from pluripotent stem cells have always been significantly lacking in at least one of the following properties: 1) functional properties related to insulin-production and glucose signaling response, 2) mature phenotype such as biochemical markers or cell structures, 3) efficiency in production of differentiated cells. Described herein is multistep differentiation protocol which substantially overcomes all of the existing limitations. Pluripotent stem cells, including induced pluripotent stem cells (iPSCs), and embryonic stem cells (ESCs) can be differentiated using an embryoid body (EB) formation step, followed by B maturation via endothelial cells (EC) co-culturing and incubation with a sequential series of bone morphogenic protein (BMP)-related growth factor cocktails. The resulting cells displayed functional properties, including insulin-production and glucose signaling response, and mature phenotype of C-peptide expression.
    Type: Grant
    Filed: February 21, 2014
    Date of Patent: March 5, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dodanim Talavera-Adame, Donald C. Dafoe
  • Publication number: 20240067933
    Abstract: Mechanical chopping has been successfully used to expand both fetal and iPSC-derived neural progenitor cells to scales suitable for early phase clinical trials. However, this method is time-consuming, labor-intensive, and challenging to implement at larger scales. Described herein are methods, apparatuses and systems for a novel in-line passaging technique that maintains the expansion rate and cellular identity of mechanical chopping but that is faster, scalable, and can be implemented in a fully sealed system.
    Type: Application
    Filed: October 22, 2020
    Publication date: February 29, 2024
    Applicant: Cedars-Sinai Medical Center
    Inventors: Alexander LAPERLE, Aaron FULTON, Clive N. SVENDSEN
  • Patent number: 11911470
    Abstract: Provided herein are methods for treating pancreatic cancer using a combination of radiotherapy and an agent that inhibits binding of PD-L1 to PD1 (e.g., durvalumab).
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: February 27, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventor: Richard Tuli
  • Patent number: 11913022
    Abstract: Human induced pluripotent stem cells (iPSCs) can give rise to multiple cell types and hold great promise in regenerative medicine and disease modeling applications. The Inventors herein developed a reliable two-step protocol to generate human mammary-like organoids from iPSCs. Non-neural ectoderm cell-containing spheres, referred to as mEBs, were first differentiated and enriched from iPSCs using MammoCult medium. Gene expression profile analysis suggested that mammary gland function-associated signaling pathways were hallmarks of 10-d differentiated mEBs. The Inventors generated mammary-like organoids from 10-d mEBs using 3D floating mixed gel culture and a three-stage differentiation procedure. These organoids expressed common breast tissue, luminal, and basal markers, including estrogen receptor, and could be induced to produce milk protein. These results demonstrate that human iPSCs can be directed in vitro toward mammary lineage differentiation.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: February 27, 2024
    Assignee: Cedars-Sinai Medical Center
    Inventors: Ying Qu, Xiaojiang Cui, Dhruv Sareen, Armando E. Giuliano